Category Archives: pricing
By Guest Blogger | Published: March 19, 2014
by Leela Barham The incremental cost effectiveness ratio (ICER) – or the threshold for determining whether the costs of a new medicine are worth it – has been controversial since it’s inception. There are those who deny that anyone can put a price-tag on life; those that accept the concept but are happy to let […]
By Julian Upton | Published: March 19, 2014
Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
By William Looney | Published: March 18, 2014
Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
By Reflector | Published: March 10, 2014
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.
By Guest Blogger | Published: February 21, 2014
By James Robinson. Any pricing or revenue management initiative is only as good as the information on which it is based. However, too many pharma companies continue to adopt a fragmented, siloed data approach which fails to make the most of this critical business asset.